Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumescent Antibiotic Injection for Chronic Wounds
NCT06327113Phase 2Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cefazolin in Chronic wound (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Adverse Events at 6 months. Started May 2024; status: recruiting.
02
Drugs
cefazolin
03
Conditions
Chronic wound
Beyond the preview
Go deeper on NCT06327113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327113.